Skip Navigation

George P. Canellos, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Institute Physician
  • William Rosenberg Professor of Medicine, Emeritus, Harvard Medical School

Centers/Programs

Clinical Interests

  • Chronic lymphocytic leukemia
  • Lymphoma

Diseases Treated

  • Lymphoma, Hodgkin
  • Lymphoma, Non-Hodgkin

Contact Information

  • Appointments617-632-6246 (new)
    617-632-3470 (follow-up)
  • Office Phone Number617-632-3470
  • Fax617-632-3477

Bio

Dr. Canellos received his MD in 1960 from Columbia University. After internship and residency at Massachusetts General Hospital, he was a clinical associate at the National Cancer Institute and a research fellow at the Royal Postgraduate Medical School in London. From 1975 to 1995, he served as chief of DFCI's Division of Medical Oncology and as medical director for network development for Dana-Farber/Partners CancerCare. He is currently a senior physician at DFCI and Brigham and Women's Hospital. He is the former Editor-in-Chief of the Journal of Clinical Oncology and President of the American Society of Clinical Oncology.

Board Certification:

  • Hematology, 1972
  • Internal Medicine, 1967
  • Medical Oncology, 1973

Fellowship:

  • Massachusetts General Hospital, Medicine
  • National Cancer Institute, Medicine

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Columbia University College of Physicians & Surgeons

Recent Awards:

  • 2020 Giants of Cancer Care® Award, Lymphoma
  • Statesman Award, American Society of Clinical Oncology 2007
  • Karl Musshof Award from the 7th International Hodgkin Lymphoma Symposium 2007
  • Frank S. Moran Clinical Research Award, University of Michigan Cancer Center 2006
  • San Salvatore Foundation Award at the 9th International Conference on Lymphoma. 2005
  • Ellis Island Foundation Medal of Honor 2004
  • Key to the Cure Award, The Cure for Lymphoma Foundation 1999
  • Honorary Doctor of Science, University of Athens, Greece 1997
  • Distinguished Service Award for Scientific Achievement, American Society of Clinical Oncology 1996
  • Fellowship, Royal College of Physicians London and Edinburgh 1991

Research

Diagnosis and Treatment of Lymphoma

Our research interests span a broad area of cytotoxic chemotherapeutic agents as well as biological agents for the treatment of malignant diseases. As former chair of the Lymphoma Committee of the Cancer and Leukemia Group B, a national cooperative trials group, Dr. Canellos initiated clinical trials in close collaboration with other groups. These trials search for answers concerning many issues, such as: -The optimal tolerable chemotherapy regimen for the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma- The integration of antibody therapy with cytotoxic agents for the treatment of these diseases- The role of early high-dose autologous transplantation in the management of poor-prognosis patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.In addition, new initiatives are under way in the use of radioimmunotherapy combined with cytotoxic therapy and the development of new agents for the treatment of lymphoma. We are exploring diagnostics to define the presence of residual disease using positron emission tomographic (PET) scans and a comparison with gallium/single photon emission computed tomography. SPECT was pioneered at DFCI for the treatment of lymphoma, and has helped to identify those patients at particularly high risk following cytotoxic treatment.He continues to be the "senior statesman" in the lymphoma group.

Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2018 04 19; 378(16):1560.
View in: PubMed

Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna. Tumori. 2016 Mar-Apr; 102(2):124-6.
View in: PubMed

Gianni Bonadonna (1934-2015). Leuk Lymphoma. 2016; 57(4):739.
View in: PubMed

Gianni Bonadonna: A Personal Remembrance. Oncologist. 2015 Nov; 20(11):1348-9.
View in: PubMed

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
View in: PubMed

Advanced DLBCL: as systemic therapy improves, the need for RT diminishes. Oncology (Williston Park). 2014 Dec; 28(12):1085-6.
View in: PubMed

Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014 Jan 20; 32(3):163-8.
View in: PubMed

Treatment for favorable localized Hodgkin lymphoma: the final answer is awaited. Oncology (Williston Park). 2012 Dec; 26(12):1199-200, 1202.
View in: PubMed

Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012 Nov; 53(11):2143-50.
View in: PubMed

Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful? J Clin Oncol. 2012 Jun 20; 30(18):2171-2.
View in: PubMed

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012 May; 97(5):758-65.
View in: PubMed

Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy? Curr Hematol Malig Rep. 2011 Sep; 6(3):180-6.
View in: PubMed

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19; 117(20):5314-20.
View in: PubMed

Hematology in 2010: New therapies and standard of care in oncology. Nat Rev Clin Oncol. 2011 Feb; 8(2):67-8.
View in: PubMed

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. Ann Oncol. 2011 Apr; 22(4):910-915.
View in: PubMed

Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol. 2010 Mar 20; 28(9):1611-5.
View in: PubMed

Is chemotherapy alone for early Hodgkin lymphoma an emerging therapeutic option? Oncologist. 2009 Dec; 14(12):1167-8.
View in: PubMed

Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009 Dec 10; 361(24):2390-1.
View in: PubMed

What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin's lymphoma? J Clin Oncol. 2010 Jan 01; 28(1):e8.
View in: PubMed

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8.
View in: PubMed

Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma. 2009 Oct; 50(10):1606-17.
View in: PubMed

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74.
View in: PubMed

What constitutes "improved prognosis"? J Clin Oncol. 2008 Apr 20; 26(12):1913-4.
View in: PubMed

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25.
View in: PubMed

Relapsed and refractory Hodgkin's lymphoma: new avenues? Hematol Oncol Clin North Am. 2007 Oct; 21(5):929-41.
View in: PubMed

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Leuk Lymphoma. 2007 Jul; 48(7):1313-9.
View in: PubMed

High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leuk Lymphoma. 2007 May; 48(5):870-80.
View in: PubMed

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol. 2007 Jun; 18(6):1071-9.
View in: PubMed

Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007 Jan; 48(1):97-103.
View in: PubMed

Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906. Leuk Lymphoma. 2006 Aug; 47(8):1511-7.
View in: PubMed

The cancer and leukemia group B lymphoma committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3572s-5s.
View in: PubMed

Where does hematology end and oncology begin? Questions of professional boundaries and medical authority. J Clin Oncol. 2006 Jun 01; 24(16):2583-8.
View in: PubMed

Introduction to a special series of unique entities within the spectrum of large-cell lymphoma. Oncologist. 2006 Apr; 11(4):374.
View in: PubMed

Clinical trials in North America. Eur J Haematol Suppl. 2005 Jul; (66):121-4.
View in: PubMed

Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. J Clin Oncol. 2005 Jun; 23(16_suppl):6530.
View in: PubMed

Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. J Clin Oncol. 2005 Jul 20; 23(21):4574-6.
View in: PubMed

Lymphoma: present and future challenges. Semin Hematol. 2004 Oct; 41(4 Suppl 7):26-31.
View in: PubMed

How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol. 2004 Apr 15; 22(8):1532-3.
View in: PubMed

Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004 Apr 01; 100(7):1438-48.
View in: PubMed

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004 Jan; 45(1):85-92.
View in: PubMed

Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. Cancer. 2003 Sep 01; 98(5):978-82.
View in: PubMed

Prognostic factors in large-cell lymphoma. Clin Adv Hematol Oncol. 2003 May; 1(5):269-70.
View in: PubMed

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol. 2003 Feb 15; 21(4):607-14.
View in: PubMed

Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol. 2003 Feb; 14(2):268-72.
View in: PubMed

Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002 May 02; 346(18):1417-8.
View in: PubMed

Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002 Apr 15; 20(8):2101-8.
View in: PubMed

New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top. J Clin Oncol. 2002 Feb 01; 20(3):607-9.
View in: PubMed

Lymphomas of the breast: primary and secondary involvement. Cancer. 2002 Jan 01; 94(1):6-13.
View in: PubMed

Primary treatment of Hodgkin's disease. Ann Oncol. 2002; 13 Suppl 4:153-8.
View in: PubMed

Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002; 20(5-6):686-92.
View in: PubMed

Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol. 2002; 13 Suppl 1:112-6.
View in: PubMed

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer. 2001 Jul 15; 92(2):207-17.
View in: PubMed

Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. Health Psychol. 2001 Jan; 20(1):71-5.
View in: PubMed

Burnout: caring for the caregivers. Oncologist. 2000; 5(5):425-34.
View in: PubMed

A new addition to the Journal of Clinical Oncology: the art of oncology--when the tumor is not the target. J Clin Oncol. 2000 Jan; 18(1):3.
View in: PubMed

Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051). Cancer. 1999 Oct 15; 86(8):1590-5.
View in: PubMed

The lymphomas. Semin Hematol. 1999 Oct; 36(4 Suppl 7):84-94.
View in: PubMed

Clinical research saves money: reflections on high-dose therapy of breast cancer. J Clin Oncol. 1999 Jul; 17(7):1965-6.
View in: PubMed

Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study. Am J Clin Oncol. 1999 Jun; 22(3):218-22.
View in: PubMed

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr; 17(4):1244.
View in: PubMed

Mediastinal large cell lymphoma: prognostic significance of CT findings at presentation and after treatment. Oncology. 1998 Jul-Aug; 55(4):284-8.
View in: PubMed

Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol. 1998 Mar; 9(3):297-306.
View in: PubMed

Treatment of relapsed Hodgkin's disease: strategies and prognostic factors. Ann Oncol. 1998; 9 Suppl 5:S91-6.
View in: PubMed

Selection bias in trials of transplantation for metastatic breast cancer: have we picked the apple before it was ripe? J Clin Oncol. 1997 Oct; 15(10):3169-70.
View in: PubMed

Stage IA-IIB Hodgkin's disease: management and outcome of extensive thoracic involvement. Int J Radiat Oncol Biol Phys. 1997 Sep 01; 39(2):361-9.
View in: PubMed

Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1997 Sep; 15(9):3060-6.
View in: PubMed

CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma. J Clin Oncol. 1997 May; 15(5):1713-6.
View in: PubMed

Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol. 1997 Apr; 15(4):1631-7.
View in: PubMed

Is CHOP the standard of therapy for poor-prognosis large-cell lymphoma? Ann Oncol. 1997; 8 Suppl 1:61-2.
View in: PubMed

Primary mediastinal large-B-cell lymphoma: radiologic findings at presentation. AJR Am J Roentgenol. 1996 Aug; 167(2):425-30.
View in: PubMed

Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD? Leukemia. 1996 Jun; 10 Suppl 2:s68.
View in: PubMed

Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood. 1996 May 01; 87(9):3625-32.
View in: PubMed

Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. J Clin Oncol. 1996 May; 14(5):1589-98.
View in: PubMed

Current strategies for early Hodgkin's disease. Ann Oncol. 1996; 7 Suppl 4:91-3.
View in: PubMed

High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol. 1995 Dec; 13(12):2916-23.
View in: PubMed

Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B. J Clin Oncol. 1995 Aug; 13(8):2005-11.
View in: PubMed

Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am. 1995 May-Jun; 1(1):33-42.
View in: PubMed

Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. J Clin Oncol. 1995 Apr; 13(4):947-52.
View in: PubMed

Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy. J Clin Oncol. 1994 Dec; 12(12):2567-72.
View in: PubMed

ASCO 30 years later: the state of the Society. J Clin Oncol. 1994 Nov; 12(11):2510-3.
View in: PubMed

The cellular biology of the Reed-Sternberg cell. Blood. 1994 Aug 15; 84(4):1005-19.
View in: PubMed

Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol. 1994 Apr; 45(4):283-7.
View in: PubMed

Quality of life in patients with limited small-cell carcinoma of the lung receiving chemotherapy with or without radiation therapy, for cancer and leukemia group B. Psychother Psychosom. 1994; 62(3-4):193-9.
View in: PubMed

High-dose therapy: here to stay or just visiting? J Clin Oncol. 1994 Jan; 12(1):5-6.
View in: PubMed

Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma. Ann Oncol. 1994; 5 Suppl 2:121-2.
View in: PubMed

Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. J Clin Oncol. 1993 Nov; 11(11):2081-9.
View in: PubMed

Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993 Jul; 11(7):1336-43.
View in: PubMed

Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin disease in relapse after initial combination chemotherapy. Cancer. 1993 Jul 01; 72(1):207-12.
View in: PubMed

Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine. Am J Hematol. 1993 Jun; 43(2):95-102.
View in: PubMed

Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes. J Natl Cancer Inst. 1993 May 19; 85(10):812-7.
View in: PubMed

Primary Ki-1 anaplastic large-cell lymphoma in adults: clinical characteristics and therapeutic outcome. J Clin Oncol. 1993 May; 11(5):937-42.
View in: PubMed

Prognostic factors for patients with Hodgkin disease in first relapse. Cancer. 1993 Apr 15; 71(8):2613-20.
View in: PubMed

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993 Apr 15; 71(8):2585-97.
View in: PubMed

Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer. 1993 Mar 01; 71(5):1857-66.
View in: PubMed

Myelosuppression and "conventional" chemotherapy: what price, what benefit? J Clin Oncol. 1993 Jan; 11(1):1-2.
View in: PubMed

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol. 1993 Jan; 11(1):155-60.
View in: PubMed

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19; 327(21):1478-84.
View in: PubMed

Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer. 1992 Nov 15; 70(10):2508-16.
View in: PubMed

Current therapeutic strategies in Hodgkin's disease. Ann Oncol. 1992 Sep; 3 Suppl 4:67-8.
View in: PubMed

The second chance for advanced Hodgkin's disease. J Clin Oncol. 1992 Feb; 10(2):175-7.
View in: PubMed

Long-term followup of 150 patients with testicular cancer treated at a single institution. J Urol. 1992 Jan; 147(1):82-8.
View in: PubMed

Burnout syndrome in the practice of oncology: results of a random survey of 1,000 oncologists. J Clin Oncol. 1991 Oct; 9(10):1916-20.
View in: PubMed

Small non-cleaved cell lymphoma in adults. Am J Hematol. 1991 Sep; 38(1):40-7.
View in: PubMed

Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. Cancer. 1991 Aug 15; 68(4):699-705.
View in: PubMed

Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991 Jul; 9(7):1196-203.
View in: PubMed

Hodgkin's disease: controversies and challenges for the future. Haematologica. 1991 Jul-Aug; 76(4):263-79.
View in: PubMed

Has the MOPP era ended? Br J Cancer. 1991 Apr; 63(4):483.
View in: PubMed

Report of the first workshop on prognostic factors in large-cell lymphomas. Ann Oncol. 1991 Feb; 2 Suppl 2:213-7.
View in: PubMed

Will doxorubicin-containing regimens replace MOPP and its variants? Leukemia. 1991; 5 Suppl 1:50-2.
View in: PubMed

Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol. 1991 Jan; 2 Suppl 1:1-7.
View in: PubMed

Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol. 1990 Dec; 8(12):1966-70.
View in: PubMed

Who should pay for clinical research? J Clin Oncol. 1990 Nov; 8(11):1775-6.
View in: PubMed

Adjuvant systemic therapy for patients with node-negative tumors. Cancer. 1990 May 01; 65(9 Suppl):2132-47.
View in: PubMed

Clinical characteristics of the blast phase of chronic granulocytic leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):359-67.
View in: PubMed

Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Semin Oncol. 1990 Feb; 17(1 Suppl 2):2-6.
View in: PubMed

Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol. 1990 Feb; 8(2):257-65.
View in: PubMed

The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol. 1990 Jan; 8(1):84-93.
View in: PubMed

High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. Cancer. 1989 Nov 15; 64(10):2014-8.
View in: PubMed

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989 Nov; 7(11):1630-6.
View in: PubMed

Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood. 1989 Nov 01; 74(6):2203-11.
View in: PubMed

Recent issues in chemotherapy for Hodgkin's disease. Curr Opin Oncol. 1989 Oct; 1(1):29-31.
View in: PubMed

Stage IA-IIB Hodgkin's disease: staging and treatment of patients with large mediastinal adenopathy. J Clin Oncol. 1989 Aug; 7(8):1059-65.
View in: PubMed

Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol. 1989 Jul; 34(1):88-93.
View in: PubMed

Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J Clin Oncol. 1989 May; 7(5):613-8.
View in: PubMed

Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease. Cancer. 1989 Mar 15; 63(6):1060-4.
View in: PubMed

Treatment of chronic granulocytic leukemia in blastic crisis. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:131-2.
View in: PubMed

The role of alkylating agents in acute and chronic leukemia. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:46-7.
View in: PubMed

Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Am J Clin Oncol. 1988 Dec; 11(6):623-6.
View in: PubMed

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol. 1988 Oct; 6(10):1576-83.
View in: PubMed

The dose dilemma. J Clin Oncol. 1988 Sep; 6(9):1363-4.
View in: PubMed

Surgical therapy of localized abdominal non-Hodgkin's lymphomas. Surgery. 1988 Jun; 103(6):609-14.
View in: PubMed

Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988 Jun; 6(6):931-3.
View in: PubMed

Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Semin Hematol. 1988 Apr; 25(2 Suppl 2):58-65.
View in: PubMed

Systemic therapy of breast cancer. Med J Aust. 1988 Jan 18; 148(2):88-91.
View in: PubMed

Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11; 316(24):1499-505.
View in: PubMed

The case for high-dose chemotherapy: is it chemotherapy's last gamble? Eur J Cancer Clin Oncol. 1987 Apr; 23(4):351-5.
View in: PubMed

The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol. 1987 Apr; 24(2 Suppl 1):2-7.
View in: PubMed

Experimental approaches in the treatment of lymphoma. Baillieres Clin Haematol. 1987 Mar; 1(1):205-21.
View in: PubMed

New agents and new medical treatments for advanced breast cancer. Semin Oncol. 1987 Mar; 14(1):34-64.
View in: PubMed

Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood. 1987 Feb; 69(2):597-604.
View in: PubMed

Splenic enlargement and hyperfunction as indications for splenectomy in chronic leukemia. Ann Surg. 1987 Jan; 205(1):13-7.
View in: PubMed

Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma. NCI Monogr. 1987; (5):71-6.
View in: PubMed

Monoclonal antibodies: their use in bone marrow transplantation. Prog Hematol. 1987; 15:137-81.
View in: PubMed

Phase II trial of m-AMSA therapy in refractory Hodgkin's disease and non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 7972. Cancer Treat Rep. 1986 Oct; 70(10):1233-4.
View in: PubMed

Relapse with nodular lymphoma following combination chemotherapy for diffuse non-Hodgkin's lymphoma. Am J Clin Oncol. 1986 Oct; 9(5):420-3.
View in: PubMed

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986 Jun; 104(6):757-65.
View in: PubMed

Hormonal agents and treatment of cancer. Urology. 1986 Jan; 27(1 Suppl):4-8.
View in: PubMed

Duration of therapy in adjuvant chemotherapy trials. NCI Monogr. 1986; (1):95-8.
View in: PubMed

Role of 99mTc methylene diphosphonate bone imaging in the management of lymphoma. Cancer Treat Rep. 1985 Dec; 69(12):1347-51.
View in: PubMed

Interferon in the treatment of malignant lymphoma. Semin Oncol. 1985 Dec; 12(4 Suppl 5):25-9.
View in: PubMed

Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985 Dec; 66(6):1352-7.
View in: PubMed

Bone marrow transplantation as salvage therapy in advanced Hodgkin's disease: allogeneic or autologous. J Clin Oncol. 1985 Nov; 3(11):1451-4.
View in: PubMed

Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. J Clin Oncol. 1985 Oct; 3(10):1301-8.
View in: PubMed

Chronic granulocytic leukemia: the heterogeneity of stem cell differentiation within a single disease entity. Semin Oncol. 1985 Sep; 12(3):281-8.
View in: PubMed

Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone. J Clin Oncol. 1985 Sep; 3(9):1166-73.
View in: PubMed

Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171. Cancer Treat Rep. 1985 Jun; 69(6):719-20.
View in: PubMed

The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol. 1985 May; 3(5):637-40.
View in: PubMed

Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol. 1985 Apr; 3(4):490-4.
View in: PubMed

Reduction of fatal complications from combined modality therapy in Hodgkin's disease. J Clin Oncol. 1985 Apr; 3(4):501-5.
View in: PubMed

Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells. Am J Hematol. 1985 Mar; 18(3):243-9.
View in: PubMed

Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Cancer Treat Rep. 1984 Nov; 68(11):1343-50.
View in: PubMed

High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma. Am J Med. 1984 Nov; 77(5):845-50.
View in: PubMed

Phase II trial of etoposide in previously treated small cell carcinoma of the lung. Cancer Treat Rep. 1984 Nov; 68(11):1413-4.
View in: PubMed

Therapy-related leukemia: a necessary complication of successful systemic chemotherapy? J Clin Oncol. 1984 Oct; 2(10):1077-9.
View in: PubMed

Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol. 1984 Oct; 20(10):1233-8.
View in: PubMed

Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet. 1984 Aug 25; 2(8400):427-31.
View in: PubMed

The treatment of locally advanced breast cancer. J Clin Oncol. 1984 Mar; 2(3):149-51.
View in: PubMed

Chemotherapy of refractory germ cell cancer with Etoposide. J Clin Oncol. 1983 Nov; 1(11):706-9.
View in: PubMed

Treatment and surgical staging of testicular and primary extragonadal germ cell cancer. JAMA. 1983 Oct 07; 250(13):1733-41.
View in: PubMed

Autologous bone-marrow transplantation: host effects of high-dose BCNU. J Clin Oncol. 1983 Oct; 1(10):610-20.
View in: PubMed

Computed tomography of the abdomen and pelvis in non-Hodgkin lymphoma. J Comput Assist Tomogr. 1983 Oct; 7(5):846-50.
View in: PubMed

Clinical value of ultrasonography for the management of non-Hodgkin lymphoma patients as compared with abdominal computed tomography. J Comput Assist Tomogr. 1983 Aug; 7(4):666-9.
View in: PubMed

Evidence for genetic restriction in the suppression of erythropoiesis by a unique subset of T lymphocytes in man. J Clin Invest. 1983 Aug; 72(2):694-706.
View in: PubMed

High-dose gallium imaging in lymphoma. Am J Med. 1983 Aug; 75(2):327-31.
View in: PubMed

Phase I trial of mitoxantrone by 24-hour continuous infusion. Cancer Treat Rep. 1983 May; 67(5):435-8.
View in: PubMed

T-cell surface antigens in a patient with blast crisis of chronic myeloid leukemia. Blood. 1983 Apr; 61(4):640-4.
View in: PubMed

Pulmonary complications associated with combination chemotherapy programs containing bleomycin. Am J Med. 1983 Apr; 74(4):557-63.
View in: PubMed

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol. 1983 Feb; 1(2):91-8.
View in: PubMed

Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control study. Cancer. 1983 Feb 01; 51(3):396-401.
View in: PubMed

Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
View in: PubMed

Chemotherapy in the treatment of Hodgkin's disease. Semin Hematol. 1983 Jan; 20(1):1-24.
View in: PubMed

Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer. 1982 Dec 15; 50(12):2708-21.
View in: PubMed

Pulmonary complications of chemotherapy regimens containing bleomycin. AJR Am J Roentgenol. 1982 Sep; 139(3):455-61.
View in: PubMed

Phase II trial of combination methyl-GAG and vinblastine in the treatment of metastatic renal adenocarcinoma. Cancer Treat Rep. 1982 Jul; 66(7):1585-6.
View in: PubMed

Occasional notes. The management of early breast cancer. N Engl J Med. 1982 Jun 10; 306(23):1430-2.
View in: PubMed

Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease. Cancer Treat Rep. 1982 Apr; 66(4):1015-22.
View in: PubMed

Histologic progression in non-Hodgkin's lymphoma. Blood. 1982 Feb; 59(2):258-64.
View in: PubMed

Effect of chemotherapy and irradiation on interactions between stromal and hemopoietic cells in vitro. Scan Electron Microsc. 1982; (Pt 1):359-65.
View in: PubMed

Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981 May 15; 47(10):2414-21.
View in: PubMed

High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg. 1981 Apr; 54(4):455-60.
View in: PubMed

Breast cancer after Hodgkin's disease in two sisters. Cancer. 1981 Jan 01; 47(1):200-2.
View in: PubMed

Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. Cancer Treat Rep. 1981; 65 Suppl 1:125-9.
View in: PubMed

Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma. Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):17-20.
View in: PubMed

Prolonged disease-free survival in advanced breast cancer treated with "super-CMF" adriamycin: an alternating regimen employing high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep. 1981; 65 Suppl 1:67-75.
View in: PubMed

Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:137-40.
View in: PubMed

VP-16-213. A phase II trial using a weekly schedule. Cancer Clin Trials. 1981; 4(4):465-7.
View in: PubMed

Structural and functional effects of adriamycin on cardiac cells in vitro. Cancer Res. 1980 Nov; 40(11):3901-9.
View in: PubMed

Successful treatment of metastatic sarcomas with cyclophosphamide, adriamycin, and DTIC (CAD). Cancer. 1980 Oct 15; 46(8):1722-6.
View in: PubMed

Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA). Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1067-71.
View in: PubMed

Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct; 69(4):585-94.
View in: PubMed

cis-Diamminedichloroplatinum(II) therapy for advanced ovarian cancer. Cancer Treat Rep. 1980 Oct-Nov; 64(10-11):1147-8.
View in: PubMed

Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer. 1980 Aug 15; 46(4):669-74.
View in: PubMed

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med. 1980 May; 92(5):587-95.
View in: PubMed

Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer. 1980 Apr 01; 45(7):1556-7.
View in: PubMed

High-dose thymidine infusions in patients with leukemia and lymphoma. Blood. 1980 Apr; 55(4):580-9.
View in: PubMed

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980 Mar; 68(3):370-6.
View in: PubMed

Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980 Mar; 68(3):356-62.
View in: PubMed

Cancer of the breast: the past decade (second of two parts). N Engl J Med. 1980 Jan 10; 302(2):78-90.
View in: PubMed

Cancer of the breast: the past decade (first of two parts). N Engl J Med. 1980 Jan 03; 302(1):17-30.
View in: PubMed

Treatment of acute nonlymphocytic leukemia with neocarzinostatin. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1853-6.
View in: PubMed

Phase I trial of bruceantin. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1929-32.
View in: PubMed

Chemotherapy of advanced non-Hodgkin's lymphoma. Clin Haematol. 1979 Oct; 8(3):667-84.
View in: PubMed

Sequential combination chemotherapy and surgery for disseminated testicular cancer: cis-dichlorodiammineplatinum(II), vinblastine, and bleomycin remission-induction therapy followed by cyclophosphamide and adriamycin. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1681-6.
View in: PubMed

Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore). 1979 Sep; 58(5):377-84.
View in: PubMed

Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep. 1979 May; 63(5):919-23.
View in: PubMed

Treatment of refractory splenomegaly in myeloproliferative disease by splenic artery infusion. Blood. 1979 May; 53(5):1014-7.
View in: PubMed

Reconstitution or resurrection of normal stem cells in chronic granulocytic leukemia. N Engl J Med. 1979 Feb 15; 300(7):360-1.
View in: PubMed

High-dose methotrexate with leucovorin rescue in ovarian cancer: a phase II study. Cancer Treat Rep. 1979 Feb; 63(2):275-9.
View in: PubMed

Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med. 1978 Dec 07; 299(23):1261-6.
View in: PubMed

Phase I and preliminary phase II study of neocarzinostatin. Cancer Treat Rep. 1978 Dec; 62(12):2019-25.
View in: PubMed

Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer. 1978 Aug; 42(2 Suppl):1001-7.
View in: PubMed

Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Cancer. 1978 Aug; 42(2 Suppl):922-5.
View in: PubMed

Chemotherapy of the non-Hodgkin's lymphomas. Cancer. 1978 Aug; 42(2 Suppl):932-40.
View in: PubMed

The staging and treatment of non-Hodgkin's lymphoma. Br J Haematol. 1978 Aug; 39(4):477-82.
View in: PubMed

Oncologic emergencies. Semin Oncol. 1978 Jun; 5(2):225-7.
View in: PubMed

Diagnosis and treatment of Hodgkin's disease. Med Times. 1978 Mar; 106(3):30-5.
View in: PubMed

Chemotherapy (cyclophosphamide, vincristine, and prednisone) versus radiotherapy (total body irradiation) for stage III-IV poorly differentiated lymphocytic lymphoma. Cancer Treat Rep. 1978 Mar; 62(3):321-5.
View in: PubMed

Treatment of the non-Hodgkin's lymphomas. Med Times. 1978 Mar; 106(3):37-41.
View in: PubMed

Treatment of the leukemias. Med Times. 1978 Mar; 106(3):42-5, 49.
View in: PubMed

A therapeutic trial of maytansine. Cancer Clin Trials. 1978; 1(2):113-7.
View in: PubMed

High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood. 1977 Dec; 50(6):1039-47.
View in: PubMed

Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. Am J Med. 1977 Oct; 63(4):542-7.
View in: PubMed

Phase II trial with bleomycin, CCNU, and streptozotocin in patients with metastatic cancer of the breast. Cancer Treat Rep. 1977 Oct; 61(7):1365-7.
View in: PubMed

Risk of new cancers in patients with Hodgkin's disease. Cancer. 1977 Oct; 40(4 Suppl):1912-6.
View in: PubMed

Sequential staging in non-Hodgkin's lymphoma. Cancer Treat Rep. 1977 Sep; 61(6):993-7.
View in: PubMed

Advanced lymphocytic lymphoma: randomized comparisons of chemotherapy and radiotherapy, alone or in combination. Cancer Treat Rep. 1977 Sep; 61(6):1153-9.
View in: PubMed

Basophilic chronic granulocytic leukaemia with hyperhistaminaemia. Br J Haematol. 1977 Jul; 36(3):367-72.
View in: PubMed

Characteristics of blast crisis in chronic granulocytic leukemia. Blood. 1977 May; 49(5):705-14.
View in: PubMed

The treatment of chronic granulocytic leukaemia. Clin Haematol. 1977 Feb; 6(1):113-28.
View in: PubMed

The place of radiation therapy in the treatment of non-Hodgkin's lymphomas. Cancer. 1977 Feb; 39(2 Suppl):843-51.
View in: PubMed

Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard. Cancer. 1976 Nov; 38(5):1882-6.
View in: PubMed

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med. 1976 Oct; 85(4):417-22.
View in: PubMed

Chronic granulocytic leukemia. Med Clin North Am. 1976 Sep; 60(5):1001-18.
View in: PubMed

Serum ferritin concentration in untreated Hodgkin's disease. Br J Cancer. 1976 Aug; 34(2):162-6.
View in: PubMed

Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer. 1976 Aug; 38(2):1026-35.
View in: PubMed

Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Ann Intern Med. 1976 Aug; 85(2):149-54.
View in: PubMed

Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy. Blood. 1976 Jun; 47(6):1003-9.
View in: PubMed

Chronic granulocytic leukemia without the Philadelphia chromosome. Am J Clin Pathol. 1976 Apr; 65(4):467-70.
View in: PubMed

Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med. 1976 Apr; 84(4):389-92.
View in: PubMed

Effect of splenectomy on tolerance to combination chemotherapy in patients with lymphoma. Blood. 1976 Feb; 47(2):211-22.
View in: PubMed

Splenectomy in the chronic phase of chronic granulocytic leukemia. Effects in 32 patients. Ann Intern Med. 1976 Jan; 84(1):17-21.
View in: PubMed

Meningeal leukemia in the blastic phase of chronic granulocytic leukemia. Am J Med. 1975 Dec; 59(6):819-28.
View in: PubMed

Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma. Natl Cancer Inst Monogr. 1975 Oct; 42:145-8.
View in: PubMed

High dose intravenous bleomycin in the treatment of advanced lymphomas. Eur J Cancer. 1975 Sep; 11(9):623-6.
View in: PubMed

Editorial: Combination chemotherapy for breast cancer. Cancer Chemother Rep. 1975 Sep-Oct; 59(5):893-4.
View in: PubMed

Letter: second malignancies complicating Hodgkin's disease in remission. Lancet. 1975 Jun 07; 1(7919):1294.
View in: PubMed

Studies on the antitumor activity of gallium nitrate (NSC-15200) and other group IIIa metal salts. Cancer Chemother Rep. 1975 May-Jun; 59(3):599-610.
View in: PubMed

Second malignancies complicating Hodgkin's disease in remission. Lancet. 1975 Apr 26; 1(7913):947-9.
View in: PubMed

American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med. 1975 Mar; 58(3):322-9.
View in: PubMed

Results of combination chemotherapy of non-Hodgkin's lymphoma. Br J Cancer Suppl. 1975 Mar; 2:465-73.
View in: PubMed

American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med. 1975 Mar; 58(3):314-21.
View in: PubMed

Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy. Br J Cancer Suppl. 1975 Mar; 2:474-80.
View in: PubMed

Non-Hodgkin's lymphoma: patterns of relapse from complete remission after combination chemotherapy. Cancer. 1975 Feb; 35(2):354-7.
View in: PubMed

Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. Blood. 1975 Feb; 45(2):197-203.
View in: PubMed

Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975 Feb 01; 1(7901):248-50.
View in: PubMed

Letter: Combination chemotherapy for breast cancer. Br Med J. 1975 Jan 04; 1(5948):37.
View in: PubMed

Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer. 1975 Jan; 35(1):98-110.
View in: PubMed

Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecol Oncol. 1974 Dec; 2(4):489-97.
View in: PubMed

Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood. 1974 Oct; 44(4):483-7.
View in: PubMed

Procabazine induced oxidative haemolysis: relationship in vivo red cell survival. Br J Haematol. 1974 Aug; 27(4):587-95.
View in: PubMed

Letter: Leukaemia and lower-motor-neuron disease. Lancet. 1974 Jul 13; 2(7872):107-8.
View in: PubMed

Mediastinal adenopathy in granulocytic leukemia. Arch Intern Med. 1974 Jul; 134(1):135-8.
View in: PubMed

Treatment of malignant melanoma with methyl CCNU. Clin Pharmacol Ther. 1974 Jun; 15(6):617-22.
View in: PubMed

The kinetics of 67gallium incorporation into inflammatory lesions: experimental and clinical studies. J Lab Clin Med. 1974 Mar; 83(3):489-95.
View in: PubMed

Evidence for granulocytic incorporation of 67gallium in chronic granulocytic leukemia. J Lab Clin Med. 1974 Mar; 83(3):496-503.
View in: PubMed

Cyclical combination chemotherapy for advanced breast carcinoma. Br Med J. 1974 Feb 09; 1(5901):218-20.
View in: PubMed

Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. Blood. 1974 Feb; 43(2):181-9.
View in: PubMed

Hypercalcemia in malignant lymphoma and leukemia. Ann N Y Acad Sci. 1974; 230:240-6.
View in: PubMed

Recently recognized complications of cancer chemotherapy. Ann N Y Acad Sci. 1974; 230:481-8.
View in: PubMed

High-dose intermittent intravenous infusion of procarbazine (NSC-77213). Cancer Chemother Rep. 1973 Sep-Oct; 57(3):361-3.
View in: PubMed

Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet. 1973 Jun 16; 1(7816):1339-43.
View in: PubMed

Initial clinical trials with methyl-CCNU 1-(2-chlorethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU). Cancer. 1973 May; 31(5):1164-9.
View in: PubMed

Intensive chemotherapy for Hodgkin's disease: long-term complications. Natl Cancer Inst Monogr. 1973 May; 36:447-54.
View in: PubMed

Combination chemotherapy and survival in advanced Hodgkin's disease. Arch Intern Med. 1973 Mar; 131(3):388-90.
View in: PubMed

Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma. Lancet. 1973 Jan 06; 1(7793):10-4.
View in: PubMed

Philadelphia-chromosome-positive preleukaemic state. Lancet. 1972 Dec 09; 2(7789):1227-8.
View in: PubMed

A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer. 1972 Dec; 30(6):1495-504.
View in: PubMed

Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med. 1972 Nov 30; 287(22):1119-22.
View in: PubMed

Treatment of ovarian carcinoma: possibilities for progress. N Engl J Med. 1972 Oct 26; 287(17):856-62.
View in: PubMed

Pharmacologic studies in man with crystallized L-asparaginase (NSC-109229). Cancer Chemother Rep. 1972 Oct; 56(5):611-4.
View in: PubMed

Late recurrence of testicular tumor. N Engl J Med. 1972 Aug 24; 287(8):413.
View in: PubMed

Prolonged cytogenetic and hematologic remission of blastic transformation in chronic granulocytic leukemia. Cancer. 1972 Jul; 30(1):288-93.
View in: PubMed

Clinical trials with 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) given intravenously. Cancer Chemother Rep. 1972 Jun; 56(3):387-91.
View in: PubMed

Treatment of the lymphomas. Semin Hematol. 1972 Apr; 9(2):193-209.
View in: PubMed

Splenectomy for thrombocytopenia in chronic granulocytic leukemia. Cancer. 1972 Mar; 29(3):660-5.
View in: PubMed

Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med. 1972 Feb; 76(2):227-34.
View in: PubMed

Proceedings: Malignant lymphoma: treatment with combination chemotherapy. Proc Natl Cancer Conf. 1972; 7:379-90.
View in: PubMed

Proceedings: The chronic leukemias: current therapeutic concepts. Proc Natl Cancer Conf. 1972; 7:351-7.
View in: PubMed

Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood. 1971 Dec; 38(6):671-9.
View in: PubMed

Neonatal megaloblastic anemia due to inherited transcobalamin II deficiency in two siblings. N Engl J Med. 1971 Nov 18; 285(21):1163-70.
View in: PubMed

Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. N Engl J Med. 1971 Aug 26; 285(9):475-9.
View in: PubMed

Hepatocellular carcinoma with the carcinoid syndrome. Cancer. 1971 May; 27(5):1182-9.
View in: PubMed

Hypercalcemia in chronic granulocytic leukemia. Cancer. 1971 Apr; 27(4):872-80.
View in: PubMed

Effect of L-asparaginase on mouse bone marrow, assayed by in vitro culture. Blood. 1970 Sep; 36(3):385-9.
View in: PubMed

Biocmical and pharmacologic effects of L-asparaginase in man. J Lab Clin Med. 1970 May; 75(5):763-70.
View in: PubMed

Asparagine biosynthesis in human KB tumor cells: inhibitor studies with asparagine and glutamine antagonists. Cancer Res. 1970 Apr; 30(4):1081-3.
View in: PubMed

Effects of sulphydryl inhibition on the erythrocyte in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1970 Mar; 18(3):269-77.
View in: PubMed

Studies of resistance to L-asparaginase in human leukemia. Recent Results Cancer Res. 1970; 33:188-93.
View in: PubMed

L-asparaginase treatment of acute myeloblastic leukemia. Oncology. 1970; 24(5):349-57.
View in: PubMed

L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969 Nov 06; 281(19):1028-34.
View in: PubMed

l-asparaginase resistance in human leukemia--asparagine synthetase. Biochem Pharmacol. 1969 Oct; 18(10):2578-80.
View in: PubMed

Lens changes in chronic granulocytic leukemia. Possible relationship to chemotherapy. Am J Ophthalmol. 1969 Sep; 68(3):500-4.
View in: PubMed

Destructive bone lesions in chronic granulocytic leukemia. Medicine (Baltimore). 1969 Sep; 48(5):401-10.
View in: PubMed

L-asparaginase and Burkitt's lymphoma. Lancet. 1969 Aug 16; 2(7616):380.
View in: PubMed

L-asparaginase toxicity. Cancer Res. 1969 Apr; 29(4):974-5.
View in: PubMed

Asparaginase and leukaemia. Lancet. 1969 Mar 22; 1(7595):626.
View in: PubMed

Hypoalbuminemic and hypocholesterolemic effect of L-asparaginase (NSC-109,229) treatment in man--a preliminary report. Cancer Chemother Rep. 1969 Feb; 53(1):67-9.
View in: PubMed

Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). Blood. 1968 Nov; 32(5):755-66.
View in: PubMed

The effect of treatment with cytotoxic agents on mouse spleen dihydrofolate reductase activity. Cancer Res. 1967 Apr; 27(4):784-8.
View in: PubMed

Hypoglycorrhachia in meningeal carcinomatosis. Cancer. 1966 May; 19(5):691-4.
View in: PubMed

Myocardial infarction in one of a pair of twenty-seven year old identical male twins. Am J Med. 1963 May; 34:741-6.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1B14
Boston, MA 02215
Get Directions

Top